Miloš Jeseňák1, Peter Bánovčin1, Iveta Plavnická1, Jana Straková2
Primary immunodeficiencies (PID) represent a heterogeneous group of diseases with functional or morphological defects in one or several parts of immune system due to inherited genetic defects. Approximately 70-85 % of all PID are associated with the antibodies production defects. The sooner the diagnosis of PID is established, the sooner the substitution therapy with immunoglobulin could be started. This therapy significantly reduces the risk of infectious complications. Subcutaneous substitution of immunoglobulin presents effective and safe alternative option to intravenous application. The efficacy of both modalities is comparable; however, there are differences in the safety profile and the frequency of side effects. The therapy could be applied also at home.